Our data unexpectedly found that HBx can sensitize HCC cell lines to EGFR/ErbB2 TKIs, including lapatinib, erlotinib, and gefitinib, and suggest ErbB3 overexpression as a potential biomarker to predict the therapeutic efficacy of lapatinib in HCC patients. Here, ERBB2 is linked to hepatocellular carcinoma.